Find clinical trials for Alzheimer's Disease in Washington, DC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Alzheimer's Disease trials near Washington, DC, USA:
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
Washington, District of Columbia, United States and 29 other locations
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Fairfax, Virginia, United States and 67 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Baltimore, Maryland, United States and 89 other locations
reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's...
Phase 3
Fairfax, Virginia, United States and 75 other locations
progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...
Baltimore, Maryland, United States and 20 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Washington, District of Columbia, United States and 117 other locations
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...
Phase 2
Fairfax, Virginia, United States and 36 other locations
This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2...
Phase 2
Fairfax, Virginia, United States and 12 other locations
versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...
Phase 2
Fairfax, Virginia, United States and 102 other locations
administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...
Phase 2
Washington, District of Columbia, United States and 96 other locations
Clinical trials
Research sites
Resources
Legal